📈 69% of S&P 500 stocks beating the index - a historic record! Pick the best ones with AI.See top stocks

BRIEF-MGC Pharma says FDA approval granted for its cannabis based anti-ageing cosmetic products

Published 25/05/2016, 10:31 am
© Reuters.  BRIEF-MGC Pharma says FDA approval granted for its cannabis based anti-ageing cosmetic products
RGT
-

May 25 (Reuters) - MGC Pharmaceuticals Ltd MXC.AX :

* FDA approval granted and first us distribution deal signed MXC.AX

* Has received formal US food and drug administration (FDA) approval of its

first 16 cannabidiol (cbd) based anti-ageing cosmetic products

* Says MGC derma will now pursue exclusive agreements with strategic

distribution partners in key US states

* Discussions are underway to extend -agreement to include jv's focusing on

genetics, growing and medicinal cannabis value add products

* Company also currently has applications pending for similar approvals in

Canada and Australia

* Says FDA approval means that the 16 MGC derma cbd based products can be

imported and sold throughout the whole of the USA

* Source text for Eikon ID:nASX6DH1ZF

*

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.